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Targeted treatment with a tyrosine kinase inhibitor (TKI) 
is associated with high response rates and significantly 
prolonged progression-free survival in the minority of 
patients (approximately 15–20%) with advanced non-
small cell lung cancer (NSCLC) whose tumor harbors 
an epidermal growth factor receptor (EGFR) mutation, 
anaplastic lymphoma kinase (ALK) rearrangement or 
ROS1 rearrangement (1). Consistently, an exceptional 
5-year survival of 14.6% has been reported with the use of 
either gefitinib or erlotinib in EGFR-mutant cases, while 
an unprecedented 4-year survival rate of 56.6% has been 
observed in ALK-positive NSCLCs treated with first-line 
crizotinib (2,3). Furthermore, with the availability in clinical 
practice of novel second- and third-generation EGFR- and 
ALK-TKIs, that show activity even after the occurrence of 
acquired resistance to first-generation agents, the clinical 
outcome of oncogene-driven NSCLC patients is expected 
to improve further. 
On the other hand, the oncologic community has 
recently witnessed another great therapeutic progress in 
NSCLC, with the introduction for clinical use of immune 
checkpoint inhibitors, termed immunotherapy, which has 
led to a substantial improvement in the outcome of patients 
with advanced disease, achieving a 5-year survival rate of 
16% in a phase 1 study of the anti-programmed death 
protein 1 (PD-1) inhibitor nivolumab (4). 
Within this scenario, the issue on whether immunotherapy 
is specifically active in the group of patients with oncogene-
driven NSCLC is of utmost clinical relevance. To date, 
most of the data on the activity of immunotherapy 
in oncogene-driven advanced NSCLCs are derived 
from randomized phase 3 trials testing single-agent 
immunotherapy as salvage treatment of patients pretreated 
with platinum-based chemotherapy (5-7). In these studies, 
patients with EGFR mutation or ALK rearrangement were 
eligible only if pretreated not only with platinum-based 
chemotherapy but also with a targeted agent. As expected, 
the number of oncogene-addicted cases was quite low in 
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Editor’s Note:
In the era of personalized medicine, a critical appraisal new developments and controversies are essential in order to 
derived tailored approaches. In addition to its educative aspect, we expect these discussions to help younger researchers to 
refine their own research strategies.
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all the studies. Based on the results of these trials, a meta-
analysis has clearly demonstrated that immunotherapy does 
not improve survival compared to docetaxel in the subgroup 
of EGFR-mutant patients [hazard ratio (HR) for survival 
=1.11, 95% CI: 0.80–1.53, P=0.54] as opposed to EGFR 
wild type patients, in which it provides a 33% reduction in 
the risk of death (HR for survival =0.67, 95% CI: 0.60–0.75, 
P<0.001) (8). More recently, useful insights into the activity 
of immunotherapy in oncogene-driven pretreated NSCLCs 
have been produced by the “ATLANTIC” trial (9). 
In detail, this was a phase 2 trial which included a cohort 
of 111 EGFR-mutant and ALK-positive patients who 
were treated with the anti-PD ligand 1 (anti-PD-L1) 
agent durvalumab. Importantly, in this oncogene-driven 
population pretreated with a TKI, the immune checkpoint 
inhibitor was associated with a very disappointing overall 
response rate (ORR), equal to 9.8%. Remarkably, even 
when the analysis was restricted to patients with a PD-L1 
expression ≥25%, who—at least in principle—could benefit 
more from immunotherapy according to the predictive role 
of PD-L1 expression, response rate remained poor, being 
only 12.2%. 
The above described results suggest that immunotherapy 
has scanty activity in EGFR-mutant and ALK-positive 
patients pretreated with a TKI. On the other hand, its 
efficacy as upfront treatment has yet to be determined, since 
oncogene-driven NSCLC patients have been generally 
excluded from the majority of clinical trials testing the 
efficacy of immunotherapy as first-line treatment (10). 
Despite this lack of data in the specific setting, there are a 
number of reasons why it is plausible that immunotherapy 
does not represent the ideal first-line treatment. First, a 
recent pooled analysis of 3,969 patients from 18 studies 
exploring the association between PD-L1 expression and 
EGFR mutation found that EGFR-mutant NSCLCs were 
less likely to be PD-L1-positive compared to EGFR wild 
type patients, with an odds ratio of 0.59 (95% CI: 0.39–0.92, 
P<0.02) (11). Second, tumor mutation burden (TMB), 
namely the total number of non-synonymous mutations 
per coding area of a tumor genome, has been found to be 
consistently reduced in EGFR-mutant and ALK-positive 
NSCLCs compared to the EGFR wild type genotype or 
other subtypes, such as KRAS-mutant tumors (12,13). 
This finding is particularly relevant, given the emerging 
evidence that suggests TMB be a more reliable biomarker 
of sensitivity to immunotherapy than PD-L1 expression 
(14,15). Last but not least, there are now data supporting 
the presence of an uninflamed tumor microenvironment 
in NSCLCs with EGFR mutations, which is characterized 
by the absence of T-cell infiltration and the presence of 
a poorly immunogenic tumor microenvironment with a 
higher proportion of PD-L1−/CD8− tumor-infiltrating 
lymphocytes (TIL) compared to the EGFR wild type 
genotype (12). In addition, other authors have reported that 
the expression of the immunosuppressive CD73 molecule is 
induced in EGFR-mutant disease, which, in turn, may lead 
to a poorly immunogenic environment with reduced T-cell 
activation and interferon gamma signature (16). Therefore, 
also the relationship between EGFR pathway activation and 
over-expression of CD73 may be responsible for a reduced 
benefit from anti-PD-1/PD-L1 therapy.
However, although the above-mentioned data suggest 
that immunotherapy could not work as upfront treatment 
of oncogene-driven NSCLC patients, research is now 
focusing on trying to associate targeted treatment and 
immunotherapy, in order to improve patients’ outcomes 
compared to targeted therapy alone. Nevertheless, 
preclinical data support the fact that combining an 
EGFR- or ALK-TKI with an anti-PD-1 inhibitor does 
not result into a synergistic interaction (17,18). Even 
more importantly, clinical data from early phase 1 studies 
suggest that the combination of targeted therapy with 
immunotherapy may not be enough safe in either EGFR-
mutant or ALK-positive patients. More in detail, the multi-
arm phase 1b “TATTON” study evaluated the combination 
of the third-generation EGFR-TKI osimertinib (that 
is active also against the T790M mutation associated 
with resistance to first-generation TKIs) plus the anti-
PD-L1 agent durvalumab (19). The trial consisted of a 
dose escalation part conducted in EGFR-TKI-pretreated 
patients (n=23) and a dose expansion part (n=11) performed 
in EGFR-TKI-naïve patients. The osimertinib/durvalumab 
combination showed some signs of activity (ORR of 66.7% 
and 21.4% in patients with T790M positive and T790M 
negative tumour status, respectively, and 70.0% in EGFR-
mutant treatment-naïve patients). However, despite the 
single-arm design does not allow an estimation of the 
contribution of each drug to the activity of the combination, 
the observed ORRs are not necessarily better than the 
activity expected with EGFR-TKI alone. Furthermore, 
a 32% and 26% incidence of grade ≥3 treatment-related 
adverse events (TRAEs) attributed to osimertinib and 
durvalumab, respectively, was reported with this regimen. 
In addition, the trial was prematurely stopped, due to the 
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unacceptably high incidence of interstitial lung disease, 
which occurred in 38.2% of patients, being grade 3/4 in 
14.7% of cases. Another trial (NCT02088112) tested the 
combination of gefitinib plus durvalumab in EGFR-mutant 
patients who were EGFR-TKI-naïve (20). This study 
showed a promising ORR of 78.9%, but again, a 55.0% 
incidence of grade ≥3 TRAEs was noted, being mainly liver 
toxicity (increased levels of transaminases). Interestingly, 
toxicity issues have been observed also with the combination 
of an ALK-TKI with immunotherapy. In fact, a recently 
published phase 1/2 trial exploring the combination of 
crizotinib plus nivolumab in untreated ALK-TKI-naïve 
patients reported an incidence of 38.5% (5/13) of grade ≥3 
liver toxicity, which could have contributed to the two cases 
of toxic deaths that were observed in the trial (21). On this 
basis, enrollment was halted, due to unacceptable toxicity, 
and immunotherapy was discontinued in all study patients. 
With regard to activity, the combination of crizotinib and 
nivolumab produced an ORR of only 38.5%, which is much 
lower than the activity usually observed with crizotinib 
alone in the first-line treatment of ALK-positive advanced 
NSCLC patients (22). Also, in this case, beyond toxicity 
issues, the single arm design of the trial does not allow 
a definitive conclusion about comparative activity of the 
combination, but indirect comparison with single-agent 
TKI does not seem particularly encouraging.
In conclusion, there is evidence strongly suggesting 
that immunotherapy is not the most effective treatment 
in oncogene-driven patients pretreated with a TKI. Also, 
the presence of a low TMB along with an uninflamed 
tumor microenvironment does not support the use of 
immunotherapy as upfront treatment in oncogene-
driven NSCLC. In addition, early phase 1/2 studies of the 
combination of targeted therapy with immunotherapy have 
often demonstrated unexpectedly relevant toxicity, which 
calls for extreme caution and thorough evaluation of the 
optimal schedule to adopt in combination regimens. Finally, 
with all the limitation of indirect comparisons, no obvious 
increase of ORR has been observed with the combination 
of a TKI and immunotherapy compared to TKI alone. On 
this basis, we conclude that, based on the evidence currently 
available, immunotherapy should not be integrated in the 
treatment of oncogene-driven NSCLCs.
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